At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The protections extend through at least 2035, with the potential for further extensions
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The FDA is beginning rulemaking to close the “adequate provision” loophole
The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Subscribe To Our Newsletter & Stay Updated
